Modifying the Tumor Microenvironment to Make Treatment More Effective
Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
Two clinical trials in the Lustgarten Foundation’s Clinical Accelerator are testing different combinations of immunotherapy.
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer.
Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
When you start pancreatic cancer treatment it seems like everyone is speaking a language you don’t know. Here are 18 important words to help you along.
New clinical guidelines from the American Society for Radiation Oncology will help clarify the best uses of radiation treatment for pancreatic cancer.
Brad Kerr changed his pancreatic cancer treatment plan after getting a second opinion, and had neoadjuvant chemotherapy before his Whipple.
Dr. Deirdre Cohen’s research into the pancreatic microbiome has found that gut bacteria may directly influence the effectiveness of immunotherapy.